Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Depreciation (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Accumulated Depreciation data on record, last reported at $27.5 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 16.45% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $27.5 million, up 16.45%, while the annual FY2025 figure was $27.5 million, 16.45% up from the prior year.
  • Accumulated Depreciation reached $27.5 million in Q4 2025 per OCUL's latest filing, up from $23.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $27.5 million in Q4 2025 and bottomed at $15.2 million in Q4 2021.
  • Average Accumulated Depreciation over 5 years is $20.8 million, with a median of $20.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: grew 18.93% in 2021, then rose 13.62% in 2022.
  • A 5-year view of Accumulated Depreciation shows it stood at $15.2 million in 2021, then rose by 13.62% to $17.3 million in 2022, then rose by 17.26% to $20.3 million in 2023, then rose by 16.64% to $23.6 million in 2024, then rose by 16.45% to $27.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $27.5 million in Q4 2025, $23.6 million in Q4 2024, and $20.3 million in Q4 2023.